

**SECURITIES AND EXCHANGE COMMISSION**  
**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT  
Pursuant to Rule 13 or 15(d)  
of the Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported):  
**March 5, 2019**

**Zymeworks Inc.**

(Exact name of registrant as specified in its charter)

**001-38068**

(Commission File Number)

**47-2569713**

(IRS Employer  
Identification No.)

**British Columbia, Canada**  
(State or other jurisdiction  
of incorporation)

**Suite 540, 1385 West 8th Avenue, Vancouver, British Columbia, Canada**  
(Address of principal executive offices)

**V6H 3V9**  
(Zip Code)

**(604) 678-1388**  
(Registrant's telephone number, including area code)

**Not Applicable**

(Former name of former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

**ITEM 8.01 OTHER EVENTS**

The following information is filed pursuant to Item 8.01, "Other Events."

On March 5, 2019, Zymeworks Inc. (the "Company") announced that management will present at the upcoming Barclays Global Healthcare Conference taking place March 12-14, 2019 in Miami Beach, Florida.

**ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS****(d) Exhibits**

<b>Exhibit No.</b>	<b>Description</b>
<a href="#">99.1</a>	<a href="#">Press Release issued by Zymeworks Inc. on March 5, 2019</a>

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

**ZYMEWORKS INC.**

(Registrant)

Date: March 5, 2019

By: /s/ Neil Klompas  
Name: Neil Klompas  
Title: Chief Financial Officer



## Zymeworks to Present at Barclays 2019 Global Healthcare Conference

**Vancouver, Canada (March 5, 2019)** – Zymeworks Inc. (NYSE/TSX: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced that management will present at the upcoming Barclays Global Healthcare Conference taking place March 12-14, 2019 in Miami Beach, Florida.

The Company's presentation will be on March 12, 2018 at 9:00 a.m. ET.

Interested parties can access a live webcast of the presentation via a link from Zymeworks' website at <http://ir.zymeworks.com/events-and-presentations>, which will also host a recorded replay available afterwards.

### About Zymeworks Inc.

Zymeworks is a clinical-stage biopharmaceutical company dedicated to the development of next-generation multifunctional biotherapeutics. The Company's suite of therapeutic platforms and its fully integrated drug development engine enable precise engineering of highly differentiated product candidates. Zymeworks' lead clinical candidate, ZW25, is a novel Azymetric™ bispecific antibody currently in a Phase 1 clinical trial. The Company's second clinical candidate, ZW49, is a bispecific antibody-drug conjugate in a Phase 1 clinical trial and combines the unique design and antibody framework of ZW25 with Zymeworks' proprietary ZymeLink™ cytotoxic payload. Zymeworks is also advancing a deep preclinical pipeline in immuno-oncology and other therapeutic areas and its therapeutic platforms have been leveraged through multiple strategic partnerships with eight global biopharmaceutical companies. For more information, visit [www.zymeworks.com](http://www.zymeworks.com).

### Contacts:

#### Investors:

Ryan Dercho, Ph.D.  
(604) 678-1388  
ir@zymeworks.com

#### Media:

Angela Bitting  
(925) 202-6211  
a.bitting@comcast.net